TherapeuticsMD Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity (Deficit)
Consolidated Statements of Stockholders’ (Deficit) Equity
(In thousands)
| Common Stock · Additional Paid in · Accumulated | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Total | |
| Balance, December 31, 2021 | 8,597 | $9 | $957,730 | $(1,051,360) | $(93,621) |
| Shares issued for sale of common stock, net of cost | 565 | — | 2,454 | — | 2,454 |
| Lender warrants | — | — | 2,727 | — | 2,727 |
| Rounding for fractional shares in connection with the reverse stock split | 142 | — | — | — | — |
| Shares issued for vested restricted and performance stock units | 189 | — | — | — | — |
| Shares issued for sale of common stock related to employee stock purchase plan | 5 | — | 14 | — | 14 |
| Share-based payment award compensation costs | — | — | 11,572 | — | 11,572 |
| Net income | — | — | — | 111,997 | 111,997 |
| Balance, December 31, 2022 | 9,498 | 9 | 974,497 | (939,363) | 35,143 |
| Shares issued for vested restricted stock units | 844 | 1 | — | — | 1 |
| Share-based compensation | — | — | 1,271 | — | 1,271 |
| Shares issued for sale of common stock related to private placement sale | 1,190 | 1 | 3,149 | — | 3,150 |
| Net loss | — | — | — | (10,278) | (10,278) |
| Balance, December 31, 2023 | 11,532 | $11 | $978,917 | $(949,641) | $29,287 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.